Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of the Dihydropyrimidine Dehydrogenase (Dpd) Inhibitory Action of 5-Chloro-2,4-Dihydroxypyridine (Cdhp) as an S-1 Component
Conditions
Interventions
S-1
FT
Locations
3
United States
Premiere Oncology of Arizona
Scottsdale, Arizona, United States
Premiere Oncology, A Medical Corporation
Santa Monica, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
Start Date
September 1, 2006
Primary Completion Date
May 1, 2007
Completion Date
May 1, 2007
Last Updated
September 3, 2024
NCT06898450
NCT01247597
NCT06658951
NCT05101070
NCT05719558
NCT06625775
Lead Sponsor
Taiho Oncology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions